Organoids From Breast Cancer Patients Treated With Neoadjuvant Therapy
ConditionInvasive Breast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorIstituti Clinici Scientifici Maugeri SpA
About this trial
The aim of this study is to establish patient-derived organoid (PDO) and tumor tissue cultures from breast cancer patients, in order to create personalized, accurate, and reliable preclinical models capable of providing information on the diverse biomolecular portraits of breast cancer. These models may also be used to predict the achievement of pathological complete response after neoadjuvant chemotherapy (NAC) treatment, study the biological, molecular, genetic, and microenvironmental characteristics of each tumor, and isolate tumor-derived extracellular vesicles from the PDOs and tissues and analyze them as potential biomarkers of response to NAC.
Eligibility criteria
Qualifiers
Female subjects;
Confirmed diagnosis of breast heteroplasia
Age 1>= 8 years;
Indication for neoadjuvant chemotherapy;
Disqualifiers
Patients who have already undergone prior chemotherapy treatments;
Patients without a proven cyto-histological diagnosis of breast carcinoma;
Subjects affected by other solid tumors besides the breast lesion.
Trial design
Treatments tested in this trial
- Blood and tumor tissue collection
Treatment groups
No treatment groups listed
Sponsors and collaborators
Istituti Clinici Scientifici Maugeri SpA
Lead sponsor
ASST Fatebenefratelli Sacco
Collaborator
Università degli Studi di Brescia
Collaborator
Buzzi Children's Hospital
Collaborator
The National Research Council, Italy
Collaborator
Source ClinicalTrials.gov